Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 17, 2024 - Issue
Submit an article Journal homepage
97
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Etanercept Combined with Glucocorticoid and Gamma Globulin for Treating Children with Toxic Epidermal Necrolysis: A Case Report

Yanhua Fu1 Department of Rheumatology, Baoding Hospital of Beijing Children’s Hospital, Baoding, 071000, People’s Republic of ChinaView further author information
,
Yuanyuan Xiao2 Department of Dermatology, National Center for Children’s Health (Beijing) Children’s Hospital Affiliated to Capital Medical University, Beijing, 100045, People’s Republic of ChinaCorrespondence[email protected]
View further author information
,
Tianji Gao1 Department of Rheumatology, Baoding Hospital of Beijing Children’s Hospital, Baoding, 071000, People’s Republic of ChinaView further author information
,
Junxiu Zhang3 Department of Dermatology, Baoding Hospital of Beijing Children’s Hospital, Baoding, 071000, People’s Republic of ChinaView further author information
&
Tianjiao Wang1 Department of Rheumatology, Baoding Hospital of Beijing Children’s Hospital, Baoding, 071000, People’s Republic of ChinaView further author information
Pages 167-171 | Received 08 Oct 2023, Accepted 29 Dec 2023, Published online: 23 Jan 2024

References

  • Riano I, Cristancho C, Treadwell T. Stevens-Johnson syndrome-like reaction after exposure to pembrolizumab and recombinant zoster vaccine in a patient with metastatic lung cancer. J Investig Med High Impact Case Rep. 2020;8:2324709620914796. doi:10.1177/2324709620914796
  • Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Medicina. 2021;57(9):895. doi:10.3390/medicina57090895
  • Surowiecka A, Barańska-Rybak W, Strużyna J. Multidisciplinary treatment in toxic epidermal necrolysis. Int J Environ Res Public Health. 2023;20(3):2217. doi:10.3390/ijerph20032217
  • Coulombe J, Belzile E, Duhamel A, et al. Pediatric SJS/TEN subdued by a combination of dexamethasone, cyclosporine, and etanercept. J Cutan Med Surg. 2019;23(5):547–550. doi:10.1177/1203475419861078
  • Estébanez A, Sáez-Martín LC, Muñoz JI, et al. Levetiracetam-induced pediatric toxic epidermal necrolysis successfully treated with etanercept. Pediatr Dermatol. 2020;37(4):701–705. doi:10.1111/pde.14179
  • Gavigan GM, Kanigsberg ND, Ramien ML. Pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis halted by etanercept. J Cutan Med Surg. 2018;22(5):514–515. doi:10.1177/1203475418758989
  • Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–153. doi:10.1046/j.1523-1747.2000.00061.x
  • Yang L, Shou YH, Li F, Zhu XH, Yang YS, Xu JH. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China. Burns. 2020;46(4):959–969. doi:10.1016/j.burns.2019.10.008
  • Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35–44. doi:10.1038/sj.jid.5701033
  • Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;9. doi:10.12688/f1000research.24748.1
  • Jacobsen A, Olabi B, Langley A, et al. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev. 2022;3(3):CD013130. doi:10.1002/14651858.CD013130.pub2
  • Wang CW, Yang LY, Chen CB, et al. The Taiwan Severe Cutaneous Adverse Reaction (TSCAR) Consortium. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985–996. doi:10.1172/JCI93349
  • Singh N, Phillips M. Toxic epidermal necrolysis: a review of past and present therapeutic approaches. Skin Therapy Lett. 2022;27(5):7–13.
  • Lu XJ, Jing J, Shi X, et al. Recombinant human tumor necrosis factor-α receptor II: igG Fc fusion protein for the treatment of drug-induced toxic epidermal necrolysis: a multicenter clinical observation. Chin Jl of Dermatology. 2020;53(6):428–434. doi:10.35541/cjd.20200068
  • Zhang X, Li B, Wang L, Wang G, Fu M. Combination of recombinant human tumor necrosis factor-α receptor II fusion protein with methylprednisolone for treatment of five patients with toxic epidermal necrolysis. Chin J Dermatovenereol. 2020;34(9):1018–1022. doi:10.13735/j.cjdv.1001-7089.202002017
  • Rao Y, Tao CR. Combination of intravenous glucocorticoid and immunoglobulin in treatment of toxic epidermal necrolysis: a comparative study in twenty-five cases. Chin J Dermatovenereol. 2017;31(2):165–166. doi:10.13735/j.cjdv.1001-7089.201605112

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.